Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Kusi, Kwadwo A ^a,b   Remarque, Edmond J ^a   Riasat, Vanessa ^a,c   Walraven, Vanessa ^a,d   Thomas, Alan W ^a   Faber, Bart W ^a   Kocken, Clemens Hm ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b University of Ghana   (Ghana)

^c HAGA HOSPITAL   (Netherlands)

^d Vlietland Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; COVACCINE HTTM; DIVERSITY COVERING VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 51; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; DRUG DERIVATIVE; MANNITOL; MEMBRANE PROTEIN; OLEIC ACID; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL CHEMISTRY; CONCENTRATION (PARAMETERS); DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; GROWTH INHIBITION; HEMATOLOGICAL PARAMETERS; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA PASTORIS; PLASMODIUM FALCIPARUM; RHESUS MONKEY; VACCINE PRODUCTION; ANIMAL; BLOOD; CELL SURVIVAL; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MACACA MULATTA; MALE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; MALARIA VACCINES; MALE; MANNITOL; MEMBRANE PROTEINS; OLEIC ACIDS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; VACCINES, SUBUNIT;

EID: 79959776666     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-182     Document Type: Article

References (56)

1. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. AA Escalante AA Lal FJ Ayala, Genetics 1998 149 189 202 9584096
2. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. SD Polley DJ Conway, Genetics 2001 158 1505 1512 11514442 (Pubitemid 32783136)
3. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. O Silvie JF Franetich S Charrin MS Mueller A Siau M Bodescot E Rubinstein L Hannoun Y Charoenvit CH Kocken AW Thomas GJ Geert-Jan van Gemert RW Sauerwein MJ Blackman RF Anders G Pluschke D Mazier, J Biol Chem 2004 279 9490 9496 10.1074/jbc.M311331200 14676185 (Pubitemid 38296016)
4. Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. AW Thomas AP Waters D Carr, Mol Biochem Parasitol 1990 42 285 287 10.1016/0166-6851(90)90172-I 2270110 (Pubitemid 20283955)
5. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. DL Narum AW Thomas, Mol Biochem Parasitol 1994 67 59 68 10.1016/0166-6851(94)90096- 5 7838184 (Pubitemid 24287311)
6. Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. LH Bannister JM Hopkins AR Dluzewski G Margos IT Williams MJ Blackman CH Kocken AW Thomas GH Mitchell, J Cell Sci 2003 116 3825 3834 10.1242/jcs.00665 12902400 (Pubitemid 37185311)
7. Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. J Healer S Crawford S Ralph G McFadden AF Cowman, Infect Immun 2002 70 5751 5758 10.1128/IAI.70.10.5751-5758.2002 12228305
8. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. GH Mitchell AW Thomas G Margos AR Dluzewski LH Bannister, Infect Immun 2004 72 154 158 10.1128/IAI.72.1.154-158.2004 14688092 (Pubitemid 38018172)
9. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. T Triglia J Healer SR Caruana AN Hodder RF Anders BS Crabb AF Cowman, Mol Microbiol 2000 38 706 718 10.1046/j.1365-2958.2000.02175.x 11115107
10. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. SA Howell C Withers-Martinez CH Kocken AW Thomas MJ Blackman, J Biol Chem 2001 276 31311 31320 10.1074/jbc.M103076200 11399764 (Pubitemid 37385002)
11. The disulfide bond structure of Plasmodium apical membrane antigen-1. AN Hodder PE Crewther ML Matthew GE Reid RL Moritz RJ Simpson RF Anders, J Biol Chem 1996 271 29446 29452 10.1074/jbc.271.46.29446 8910611 (Pubitemid 26382664)
12. Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes. VK Goel X Li H Chen SC Liu AH Chishti SS Oh, Proc Natl Acad Sci USA 2003 100 5164 5169 10.1073/pnas.0834959100 12692305 (Pubitemid 36542676)
13. 19across distantly related Plasmodium species. RA O'Donnell A Saul AF Cowman BS Crabb, Nat Med 2000 6 91 95 10.1038/71595 10613831 (Pubitemid 30048533)
14. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. SH Qari YP Shi IF Goldman BL Nahlen M Tibayrenc AA Lal, Mol Biochem Parasitol 1998 92 241 252 10.1016/S0166-6851(98)00010-3 9657329
15. Plasmodium falciparum: variations within the C-terminal region of merozoite surface antigen-1. R Tolle H Bujard JA Cooper, Exp Parasitol 1995 81 47 54 10.1006/expr.1995.1091 7628566
16. A malaria merozoite surface protein (MSP1)-structure, processing and function. AA Holder MJ Blackman PA Burghaus JA Chappel IT Ling N McCallum-Deighton S Shai, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 37 42 1343798
17. Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. MJ Blackman H Whittle AA Holder, Mol Biochem Parasitol 1991 49 35 44 10.1016/0166-6851(91)90128-S 1723148
18. Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. AA Holder JS Sandhu Y Hillman LS Davey SC Nicholls H Cooper MJ Lockyer, Parasitology 1987 94 Pt 2 199 208 3295686 (Pubitemid 17043460)
19. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. MJ Blackman HG Heidrich S Donachie JS McBride AA Holder, J Exp Med 1990 172 379 382 10.1084/jem.172.1.379 1694225 (Pubitemid 20217284)
20. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. MJ Blackman IT Ling SC Nicholls AA Holder, Mol Biochem Parasitol 1991 49 29 33 10.1016/0166-6851(91)90127-R 1775158
21. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. RF Anders PE Crewther S Edwards M Margetts ML Matthew B Pollock D Pye, Vaccine 1998 16 240 247 10.1016/S0264-410X(97)88331-4 9607037 (Pubitemid 27521005)
22. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. S Dutta PV Lalitha LA Ware A Barbosa JK Moch MA Vassell BB Fileta S Kitov N Kolodny DG Heppner JD Haynes DE Lanar, Infect Immun 2002 70 3101 3110 10.1128/IAI.70.6.3101-3110.2002 12011004 (Pubitemid 34564173)
23. Specificity of the protective antibody response to apical membrane antigen 1. AN Hodder PE Crewther RF Anders, Infect Immun 2001 69 3286 3294 10.1128/IAI.69.5.3286-3294.2001 11292751 (Pubitemid 32332227)
24. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. JA Lyon E Angov MP Fay JS Sullivan AS Girourd SJ Robinson ES Bergmann-Leitner EH Duncan CA Darko WE Collins CA Long JW Barnwell, PLoS ONE 2008 3 2830 10.1371/journal.pone.0002830 18665258
25. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. DL Narum SA Ogun AW Thomas AA Holder, Infect Immun 2000 68 2899 2906 10.1128/IAI.68.5.2899-2906.2000 10768987 (Pubitemid 30253870)
26. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. S Singh K Miura H Zhou O Muratova B Keegan A Miles LB Martin AJ Saul LH Miller CA Long, Infect Immun 2006 74 4573 4580 10.1128/IAI.01679-05 16861644 (Pubitemid 44157244)
27. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. AW Stowers MC Kennedy BP Keegan A Saul CA Long LH Miller, Infect Immun 2002 70 6961 6967 10.1128/IAI.70.12.6961-6967.2002 12438375 (Pubitemid 35387931)
28. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. MJ Blackman TJ Scott-Finnigan S Shai AA Holder, J Exp Med 1994 180 389 393 10.1084/jem.180.1.389 7516416 (Pubitemid 24181090)
29. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. S Dutta JD Haynes JK Moch A Barbosa DE Lanar, Proc Natl Acad Sci USA 2003 100 12295 12300 10.1073/pnas.2032858100 14526103 (Pubitemid 37271554)
30. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. WE Collins D Pye PE Crewther KL Vandenberg GG Galland AJ Sulzer DJ Kemp SJ Edwards RL Coppel JS Sullivan CL Morris RF Anders, Am J Trop Med Hyg 1994 51 711 719 7810803
31. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. PE Crewther ML Matthew RH Flegg RF Anders, Infect Immun 1996 64 3310 3317 8757869 (Pubitemid 26256181)
32. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. MC Kennedy J Wang Y Zhang AP Miles F Chitsaz A Saul CA Long LH Miller AW Stowers, Infect Immun 2002 70 6948 6960 10.1128/IAI.70.12. 6948-6960.2002 12438374 (Pubitemid 35387930)
33. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. EJ Remarque BW Faber CH Kocken AW Thomas, Infect Immun 2008 76 2660 2670 10.1128/IAI.00170-08 18378635
34. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. KA Kusi BW Faber V Riasat AW Thomas CH Kocken EJ Remarque, PLoS ONE 2010 5 15391 10.1371/journal.pone.0015391 21082025
35. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. BW Faber EJ Remarque WD Morgan CH Kocken AA Holder AW Thomas, Infect Immun 2007 75 5947 5955 10.1128/IAI.01804-06 17938224 (Pubitemid 350207835)
36. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. JM Burns jr PR Flaherty MM Romero WP Weidanz, Vaccine 2003 21 1843 1852 10.1016/S0264-410X(03)00026-4 12706668 (Pubitemid 36428774)
37. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. JA Langermans A Schmidt RA Vervenne AJ Birkett JM Calvo-Calle M Hensmann GB Thornton F Dubovsky H Weiler E Nardin AW Thomas, Vaccine 2005 23 4935 4943 10.1016/j.vaccine.2005.05.036 15998554 (Pubitemid 41242870)
38. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. KA Kusi BW Faber AW Thomas EJ Remarque, PLoS ONE 2009 4 8110 10.1371/journal.pone.0008110 19956619
39. The use of non-human primates in research. A working group report chaired by Sir David Weatheall, 2006 http://www.acmedsci.ac.uk/images/project/nhpdownl. pdf
40. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. GE Mullen BK Giersing O Ajose-Popoola HL Davis C Kothe H Zhou J Aebig G Dobrescu A Saul CA Long, Vaccine 2006 24 2497 2505 10.1016/j.vaccine.2005.12.034 16434128 (Pubitemid 43290379)
41. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. CS Diefenbach S Gnjatic P Sabbatini C Aghajanian ML Hensley DR Spriggs A Iasonos H Lee B Dupont S Pezzulli AA Jungbluth LJ Old J Dupont, Clin Cancer Res 2008 14 2740 2748 10.1158/1078-0432.CCR-07-4619 18451240
42. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. BS Graham MJ McElrath MC Keefer K Rybczyk D Berger KJ Weinhold J Ottinger G Ferarri DC Montefiori D Stablein C Smith R Ginsberg J Eldridge A Duerr P Fast BF Haynes the AIDS Vaccine Evaluation Group, PLoS ONE 2010 5 11995 10.1371/journal.pone. 0011995 20706632
43. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. Y Wu RD Ellis D Shaffer E Fontes EM Malkin S Mahanty MP Fay D Narum K Rausch AP Miles J Aebig A Orcutt O Muratova G Song L Lambert D Zhu M Miura C Long A Saul LH Miller AP Durbin, PLoS ONE 2008 3 2636 10.1371/journal.pone.0002636 18612426
44. Clinical trials registration database. http://www.clinicaltrials.gov Identifiers NCT00702221, NCT00895466, NCT01015703
45. Effects of the anaesthetic/tranquillizer treatments on selected plasma biochemical parameters in NZW rabbits. A Gonzalez Gil JC Illera G Silvan M Illera, Laboratory Animals 2003 37 155 161 10.1258/00236770360563804 12689427 (Pubitemid 36470104)
46. The effects of prolonged ketamine-xylazine intravenous infusion on arterial blood pH, blood gases, mean arterial blood pressure, heart and respiratory rates, rectal temperature and reflexes in the rabbit. JD Wyatt RA Scott ME Richardson, Lab Anim Sci 1989 39 411 416 2530398 (Pubitemid 19225974)
47. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. JG Heldens HL Glansbeek LA Hilgers B Haenen KJ Stittelaar AD Osterhaus JF Van Den Bosch, Vaccine 2010 28 8125 8131 10.1016/j.vaccine.2010.09. 097 20950729
48. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. SJ Draper S Biswas AJ Spencer EJ Remarque S Capone M Naddeo MD Dicks BW Faber SC de Cassan A Folgori A Nicosia SC Gilbert AVS Hill, J Immunol 2010 185 7583 7595 10.4049/jimmunol.1001760 21098232
49. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. R Bodewes JH Kreijtz G van Amerongen MM Geelhoed-Mieras RJ Verburgh JG Heldens J Bedwell JM Van Den Brand T Kuiken CA van Baalen RAM Fouchier ADME Osterhaus GF Rimmelzwaan, J Virol 2010 84 7943 7952 10.1128/JVI.00549-10 20519384
50. Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). SM Johnson NW Lerche D Pappagianis JL Yee JN Galgiani RF Hector, Ann N Y Acad Sci 2007 1111 290 300 10.1196/annals.1406.042 17347333 (Pubitemid 47573038)
51. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Y Morera M Bequet-Romero M Ayala JC Velazco PP Perez JS Alba J Ancizar M Rodriguez K Cosme JV Gavilondo, Vaccine 2010 28 3453 3461 10.1016/j.vaccine.2010.02.069 20197134
52. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. S Herrera OL Fernandez O Vera W Cardenas O Ramirez R Palacios M Chen-Mok G Corradin M Arevalo-Herrera, Am J Trop Med Hyg 2011 84 12 20 10.4269/ajtmh.2011. 09-0516 21292873
53. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. W Pan D Huang Q Zhang L Qu D Zhang X Zhang X Xue F Qian, J Immunol 2004 172 6167 6174 15128804 (Pubitemid 38621222)
54. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. DE Arnot DR Cavanagh EJ Remarque AM Creasey MP Sowa WD Morgan AA Holder S Longacre AW Thomas, Clin Vaccine Immunol 2008 15 1345 1355 10.1128/CVI.00172-08 18550731
55. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. S Dutta JS Sullivan KK Grady JD Haynes J Komisar AH Batchelor L Soisson CL Diggs DG Heppner DE Lanar WE Collins JW Barnwell, PLoS ONE 2009 4 8138 10.1371/journal.pone.0008138 19997632
56. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. TR Jones N Obaldia RA Gramzinski SL Hoffman, Am J Trop Med Hyg 2000 62 675 680 11304053 (Pubitemid 32281484)